𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome

✍ Scribed by Ali Al Ameri; Charles Koller; Hagop Kantarjian; Farhad Ravandi; Srdan Verstovsek; Gautam Borthakur; Sherry Pierce; Gloria Mattiuzzi

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
142 KB
Volume
116
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Impact of remission induction chemothera
Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia
✍ Rachid Baz; Cristina Rodriguez; Alex Z. Fu; Rony Abou Jawde; Matt Kalaycio; Anja πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 124 KB πŸ‘ 1 views

## Abstract ## BACKGROUND. Significant controversy surrounds the use of remission induction chemotherapy (IC) in older adults with acute myeloid leukemia (AML). Earlier clinical trials have yielded conflicting results and possibly a minor survival benefit, often offset by a longer hospitalization

Intensive chemotherapy is not recommende
Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes
✍ Sabine Knipp; Barbara Hildebrand; Andrea KΓΌndgen; Aristoteles Giagounidis; Guido πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 147 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. It is unclear whether intensive chemotherapy is beneficial to patients with high‐risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) if they are aged β‰₯60 years. ## METHODS. The authors studied 160 patients with a median age of 67 years who received inte

Results of intensive chemotherapy in 998
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: : Predictive prognostic models for outcome
✍ Hagop Kantarjian; Susan O'Brien; Jorge Cortes; Francis Giles; Stefan Faderl; Eli πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 146 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Elderly patients (age β‰₯ 65 years) with acute myeloid leukemia (AML) generally have a poor prognosis. AML‐type therapy results are often derived from studies in younger patients and may not apply to elderly AML. Many investigators and oncologists advocate, at times, only s